115 related articles for article (PubMed ID: 18048967)
1. High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study.
Kuvaja P; Würtz SØ; Talvensaari-Mattila A; Brünner N; Pääkkö P; Turpeenniemi-Hujanen T
Cancer Biomark; 2007; 3(6):293-300. PubMed ID: 18048967
[TBL] [Abstract][Full Text] [Related]
2. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study.
Würtz SØ; Møller S; Mouridsen H; Hertel PB; Friis E; Brünner N
Mol Cell Proteomics; 2008 Feb; 7(2):424-30. PubMed ID: 17998244
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study.
Thorsen SB; Christensen SL; Würtz SO; Lundberg M; Nielsen BS; Vinther L; Knowles M; Gee N; Fredriksson S; Møller S; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2013 Dec; 13():598. PubMed ID: 24330623
[TBL] [Abstract][Full Text] [Related]
4. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Schrohl AS; Holten-Andersen MN; Peters HA; Look MP; Meijer-van Gelder ME; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 2004 Apr; 10(7):2289-98. PubMed ID: 15073104
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
6. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients.
Würtz SØ; Christensen IJ; Schrohl AS; Mouridsen H; Lademann U; Jensen V; Brünner N
Mol Cell Proteomics; 2005 Apr; 4(4):483-91. PubMed ID: 15640527
[TBL] [Abstract][Full Text] [Related]
7. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Schrohl AS; Christensen IJ; Pedersen AN; Jensen V; Mouridsen H; Murphy G; Foekens JA; Brunner N; Holten-Andersen MN
Mol Cell Proteomics; 2003 Mar; 2(3):164-72. PubMed ID: 12672830
[TBL] [Abstract][Full Text] [Related]
8. High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer.
Carpén T; Sorsa T; Jouhi L; Tervahartiala T; Haglund C; Syrjänen S; Tarkkanen J; Mohamed H; Mäkitie A; Hagström J; Mattila PS
Cancer Immunol Immunother; 2019 Aug; 68(8):1263-1272. PubMed ID: 31240326
[TBL] [Abstract][Full Text] [Related]
9. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
10. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma.
Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Breast Cancer Res Treat; 2005 Jan; 89(1):29-34. PubMed ID: 15666194
[TBL] [Abstract][Full Text] [Related]
11. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.
Tsai HP; Chen SC; Chien HT; Jan YY; Chao TC; Chen MF; Hsieh LL
World J Surg Oncol; 2012 Feb; 10():42. PubMed ID: 22339939
[TBL] [Abstract][Full Text] [Related]
12. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
[TBL] [Abstract][Full Text] [Related]
13. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
[TBL] [Abstract][Full Text] [Related]
14. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
15. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients.
Kozłowski M; Laudański W; Mroczko B; Szmitkowski M; Milewski R; Łapuć G
Adv Med Sci; 2013; 58(2):227-34. PubMed ID: 23773968
[TBL] [Abstract][Full Text] [Related]
16. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma.
Kuvaja P; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Int J Cancer; 2008 Aug; 123(4):846-51. PubMed ID: 18506691
[TBL] [Abstract][Full Text] [Related]
17. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
18. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
19. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
20. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Ho D; Huang J; Chapman JW; Leitzel K; Ali SM; Shepherd L; Parulekar WR; Ellis CE; Crescnzo RJ; Zhu L; Virk S; Nomikos D; Aparicio S; Gelmon KA; Carney WP; Lipton A
Breast Cancer Res Treat; 2017 Aug; 164(3):571-580. PubMed ID: 28484925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
